In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death.

Abstract

SOURCE CITATION:

Kalra PR, Cleland JG, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. 36347265.

• Authors: Joseph B Lerman, L Kristin Newby
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 176 Issue 4 Pg. JC40 (04 2023) ISSN: 1539-3704 [Electronic] United States
• PMID: 37011388 (Publication Type: Journal Article, Comment)

Chemical References

• ferric derisomaltose
• Maltose

Topics

• Humans
• Anemia, Iron-Deficiency (drug therapy, complications)
• Prospective Studies
• Maltose (therapeutic use)
• Iron Deficiencies
• Hospitalization
• Heart Failure (drug therapy, complications)